INTRODUCTION
Chronic hemodialysis treatment requires vascular access. This can be provided by central venous catheter, native arteriovenous fistula or arteriovenous graft interponed between arterial and venous blood vessel. A native arteriovenous fistula is considered the most favourable in terms of function, duration and absence of complications 1, 2 . There are always however, a number of patients with insufficient autologous venous vasculature where the native superficial venous vessels are hypoplastic or attrited due to previous surgical procedures. For this reason a central venous catheter is introduced or an an arteriovenous conduit is implanted in these patients 2 . Various materials -autologous, homologous and heterologous -are used as a graft. Various evaluations of these materials have been reported but the common view is that all are associated with a large number of complications [3] [4] [5] . Currently, the ePTFE conduit is preferred for its availability. A central venous catheter vascular access is indicated if acute hemodialysis procedure is necessary and all other possibilities for angioaccess have been exhausted. Despite associated complications, central venous catheters are increasingly common in Europe as well as in USA and Canada 2 . Initially, natural materials were used as autologous, homologous and heterologous vein and arteries and later artificial materials such as modified polyester and ePTFE vascular prostheses began to be used Of these, ePTFE interponate best meets the requirements of sufficient arteriograft: availability and handling, material inertness, rapid healing, low incidence of post venipuncture bleeding, resistance to infectious complications and thrombosis, and long term good cumulative access function. Conduits made of ePTFE have been used for some time. Initially they were used in surgical procedures performed on the venous system 6 . The first experience with ePTFE conduits in human arterial circulation were published in 1975 (ref. 7 ). In 1973, Volder was the first to use the eP-TFE conduit as an arteriovenous graft for hemodialysis 8 . In the course of time ePTFE conduit has became the gold standard for arteriovenous graft 5, [9] [10] [11] [12] . Currently, there are many ePTFE conduits producers and various product modifications are available. The ePTFE conduits vary in length of fibrils, wall thickness and wall reinforcement, number of wall layers, the cover of the internal surface and shape of the conduit. Conduits have been compared in a number of studies but no substantial benefits between different types have been reported 4 . Above all, the function and duration in terms of the emergence of stenotic and thrombotic complications have been monitored [13] [14] [15] [16] . These complications are essentially reparable. A more serious complication is graft infection 17 , whose spread in the organism can cause general infection. In hemodialysis patients infection is associated with high 14 P. Bachleda [18] [19] [20] [21] . Studies have shown that a vascular access is one of the most important risk factors for infection and bacteremia in hemodialysis patients 22, 23 . The hospitalization rate for these patients is double the general population and in 20% of cases the cause for hospitalization is infection 24, 25 . Epidemiologic studies have shown that angioaccess type affects the risk of infection or bacteremie emergence 22, 26 . At highest risk are patients with central venous catheter followed by patients with tunelized catheter and arteriovenous graft, while native arteriovenous fistula present low risk of infection 23, 26, 27 . In patients with central venous catheter infection, complications occur in 20 to 50% and the risk of infection is associated with the duration of catheter positioning [28] [29] [30] [31] . The lowest risk of infectious complications is in patients with native arteriovenous fistula, where the incidence is from 2 to 3% (ref. 13, 29, 32 ). In patients with arteriovenous graft the incidence of infection is from 11 to 35% (ref. 13, [32] [33] [34] [35] ), and infection complications associated with arteriovenous graft are approximately one third more than arteriovenous fistula 23 . Also later published studies have shown that the incidence of infection in arteriovenous graft is ten times more common than autologous fistula and significantly lower than central venous catheter 13, 36 . In Europe, infected graft present a problem demanding complex solution as patients autologous vasculature is usually attrited and arteriovenous graft was the final chance for angiaccess without central venous system cathetization. Arteriovenous graft infection manifests locally or can spread to the organism.
Local arteriovenous graft infection manifests as skin affection, in addition, infected grafts tend to thrombosis, perigraft hematoma and pseudoaneurysm. These complications are the leading cause of the access loss in 60%, while infection causes graft failure in 35% (ref. 37 ). The incidence of graft infection increase with length of function: there is a higher incidence in the second and third year 36 . Serious overall symptoms of infection are sepsis, metastatic infectious complications such as endocarditis, arthritis, pulmonary embolism and osteomyelitis 38 . Hospitalization due to sepsis is associated with increased incidence of myocardial infarction, congestive heart failure, cerebral stroke and peripheral artery ischemic disease in the following years 39 . Arteriovenous graft infection management includes treatment of local and general complications as well as maintaining the angioaccess. The task is to maintain functional arteriovenous graft through local treatment and antibiotics administration as long as possible.
A number of risk factors for arteriovenous graft infection have been recognized. Risk factors result from graft localization -infection is more common in lower extremities 40, 41 , insufficient antisepsis during surgical procedure 34 , technique of venipuncture with risk of hematoma creation or infection contamination 42 . Clearly, the longer the arteriovenous graft is used for hemodialysis the higher is the risk of graft infection emergence 33, 36, 43 . The incidence of arteriovenous graft infection is affected by a large number of factors such as: impaired immunosurveillance in hemodialysis patient caused by neutrophils dysfunction in uremia [44] [45] [46] , obesity, diabetes mellitus 47 , hypalbuminemia 36, 48 , insufficient personal hygiene 49 . Another risk factor is HIV infection 50, 51 . The arteriovenous graft as well as all vascular prostheses are compromised by other infectious diseases that can spread through blood circulation and colonize the conduit 52 . As in vascular surgery, the administration of antibiotics can suppress symptoms of arteriovenous graft infection. However, infection cannot be eradicated and presents a permanent risk as source for local or general infection. A considerable risk factor for bacteremia is its existing presence 23 .
Microbiology
Usually an angioaccess is infected with common skin microorganisms represented by grampositive bacteria. In most cases, the causative organism of the angioaccess infection is Staphylococcus aureus or other grampositive pathogens, like coagulase-negative staphylococci. Staphylococcus aureus is demonstrated in almost 68% cases of angioaccess infection. Other grampositive bacteria have been found in 20 to 60% (ref. 36, 53 ). Less commonly, gramnegative bacteria are the cause of infection with the demonstration in 28% of cases 36, 54 . Their occurrence is associated with the transmission from hemodialysis machines 55 . The most common route of infection entry is an angioaccess, followed by urinary tract, gastrointestinal tract and respiratory tract.
Infections caused by Staphylococcus aureus occur frequently often and are associated with more complications and worse outcomes than other infections. Metastatic skeletal infections, endocardial infections and brain abscesses are among the most serious infectious complications. Infected arteriovenous graft is the source for septic emboli as has been confirmed in 12% of infected grafts 36 .The morbidity rate in patients with bacteriemia caused by Staphylococcus aureus ranges from 13 to 44% (ref. 38, 56, 57 ). Methicilin resistant Staphylococcus aureus (MRSA) is an increasing problem in dialysis centers. A risk factor for MRSA is a previous use of antibiotics 58, 59 . An infection caused by MRSA increases the risk of 90-days mortality of 70% in comparison with an infection caused by methicilin sensitive pathogen 60 . The use of linezoloid may be beneficial in MRSA soft-tissue infection treatment 61 . The eventual drug penetration into infected grafts has not been confirmed and needs to be evaluated in further studies. Vancomycin resistant enterococci infections are also more often diagnosed in hemodialysis patients. In the USA the incidence of such infection has at least doubled 62, 63 . The possible cause is excessive use of antibiotics, especially vancomycin and the third generation of cephalosporins 62, 64 .
Prevention
Compliance with the rules of aseptic surgical techniques and accurate operating technique are the main prevention of early infectious complications following graft implantation 65 . An early infection complication is almost always associated with microbial contamination. Early infection in association with hematogenous contamina-Infectious complications of arteriovenous ePTFE grafts for hemodialysis tion is extremely rare: an incidence of 1.1% is reported 42, 66 . Besides inadequate asepsis practices in the operating room, an unqualified wound dressing can cause infection. Such complication is prevent by prophylactic use of antibiotic, e.g. cefazolin 67 . Vancomycin single administration after graft implantation was found to lead to significant decrease in early infectious complications 34 . However, the use of vancomycin increases the incidence of the vancomycin resistant enterococci 68, 69 . Also prophylactic use of rifampicin decreases the incidence of Staphylococcus aureus infection, but its administration is associated with the risk of toxic reactions and with bacterial resistance after short-term administration 70, 71 . The perigraft reaction needs to be distinguished from infectious complication. The former manifests with edema, skin erythema and heat and the presence of pain around the vascular prosthesis. The local finding can mimic graft infection. Initially, fluid collects around the prosthesis, cyst formations and later, infiltrates having a fish meat structure on the cut can occur. The perigraft reaction can arise anytime after prosthesis implantation (a few days to months). Histologically it has the structure of a chronic seroma [72] [73] [74] . In patients with renal end-stage disease the perigraft reaction incidence is higher 66 . Due to the local finding graft cannulation is not possible. The perigraft reaction was present in the type of prosthesis Diastat 75 . In practice, the usual rules for medical personnel apply. These include hand washing and, scrubbing, rinsing and disinfection of the forearms. The aseptic technique for the cannulation is also important 44 .
Diagnosis
Clinical findings such as warmth and redness of the skin, local pain, edema, serous or purulent secretion from the wound (after cannulation) or abscess usually lead to a diagnosis of infection. There may also be general symptoms of temperature and chill. Tunnel infection is extremely serious. It is associated with pus around the graft and sometimes the graft floats. A chronic fistula with purulent secretion occurs on the side of the cannulation. The early manifestation of graft infection can present as bleeding from the anastomosis. Infected arterial anastomosis of the graft on the side of the brachial artery can cause massive haemorrhage 76 . If the extent of the involvement is unclear, ultrasonography examination should be performed to detect fluid around the graft 53 . If wound or puncture secretion is present it is necessary to examine a sample of the secretion. If the patient is septic, a hemoculture tests should be done.
In terms of the infection, dysfunctional thrombosed grafts that are left in the patient are a special issue. This can be infected and become a source of infection, causing serious complications 50, 77 . In the presence of sepsis of unknown etiology, we should be aware of this potential source of infection and the patient should undergo labeled leukocyte scintigraphy 78 or positron emission tomography scanning (FDG-PET) 79 . The PET CT is considered as an easier and more accurate diagnostic method than the Indium 111-leukocyte imaging 79, 80 .
Graft Infection Therapy
Treatment for the graft infection can be conservative, surgical or, most commonly, a combination of both. In terms of surgical treatment, the principal is removal of the infected prosthesis or infected part of the prosthesis -total graftectomy (TGE), subtotal graftectomy (SGE) or partial graftectomy (PGE) 53 . In the presence of sepsis, tunnel infection or bleeding from the anastomosis, total graftectomy is indicated 81, 82 . After removal of the graft, surgical treatment of the anastomosis is required -venous anastomosis is re-sewn and arterial anastomosis is treated with a venous patch. Brachial artery ligature is indicated only when there is bleeding from the anasomosis. Exceptionally, brachial artery ligature can lead to hand ischemia. In such cases, venous bypass performed on the intact subcutis may be necessary to maintain sufficient hand circulation.
If the autologous venous circulation is extremely sclerotic, the bypass cannot be performed. Hand ischemia is preferable to life-threatening arterial bleeding. We know from practice, that the artery can be ligated, if the hand had not been in danger of ischemia while the graft was functional 83, 84 . The brachial artery can be ligated below the branching point of the deep brachial artery. The ligature is performed on the intact tissue: Generally it is safe and the results are good without ischemic complications or bleeding 85 . When the arterial anastomosis is not affected by infection, it is acceptable to leave a small piece of the prosthesis (2 to 3 mm) at the side of the arterial anastomosis and sew the lumen of the prosthesis 86, 87 . This procedure is also known as subtotal graftectomy. It is indicated in patients with infected prosthesis, but without clinical symptoms of sepsis. The procedure is beneficial as it reduces the risk of arterial and nerve injury and the risk of arterial bleeding. After the graft removal, the necrotic tissue must be removed and lavages are performed 53 . The procedure, when the brachial artery is sutured end-to-end, or when small pieces of left prosthesis are sutured, is not always radical, while the potentially infected tissue surrounding the graft in left in situ. From here the infection can spread and can cause arterial bleeding. The risk of new arterial bleeding in patients with positive hemoculture is 20%. The resection of the artery at the site of anastomosis and the replacement with a venous graft is recommended. Thus a complete infected tissue debridement is allowed. This procedure is radical in the elimination of infection and it also prevents arterial stenosis 88 . It should be followed by a microbiological examination of the prosthesis and, subsequently by targeted antibiotic treatment 19 . Before the microbiological test results are known, patients are treated empirically, usually with a combination of gentamicin or vancomycin and the third generation of cephalosporins 50, 53, 54 . Sequential antibiotic therapy is set up according to the test results. The dosage of antibiotics is renal function dependent and the treatment duration is 3 to 6 weeks on average 50, 53 . Partial graftectomy is indicated if only a part of the prosthesis is infected. The intraoperative finding is fundamental -all the parts of prosthesis, except the affected part, must be fixed in the subcutis and free of infection. In such situations, the affected part of the prosthesis is removed, the intact parts of the prosthesis are ligated and the subcutis is oversewn through-and-through at the side of the anastomosis. The infected subcutis is partitioned and a new prosthesis is implanted in the intact subcutis, connected only with the unaffected sections of the original prosthesis. This procedure allows us to dialyse the patient through the original vasculature so he or she does not need to be catheterized. However, this procedure remains controversial, while the original graft often works as a source of infection. The infection involvement is not exactly clear during the surgery and the PGE carries a risk of further infectious complications and bleeding. The PGE has been evaluated in many single-centre studies and good results have been reported in 74-80% (ref. 37, 53, 81, 82, 89 ). Although, this approach is not generally accepted. Some centers prefer the TGE since the PGE is associated with a large number of infectious complications 77 .
In some cases there is only a "local infection" presented as a skin necrosis, abscess or fistula at the point of entry of infection. The patient is generally symptom free. A graft may be infected, but the local finding is discreet and can be treated with local surgical therapy using drainage, elution and suitable antibiotic administration 81, 90 . With this approach, the majority of infections can mitigate but are not treated.
In general, prompt treatment of skin or distant infection is fundamental for preservation of the graft. Only well-timed and potent antibiotic therapy can positively affect the incipient skin and subcutis involving local infection. The infected graft that cannot be treated by antibiotic therapy, must be resected or completely removed. The next step is to provide an alternative angioaccess, usually catheterization of the central venous system, and intravenous antibiotic therapy. After the resolution of infection, a sequential procedure providing a permanent angioaccess by graft placement is scheduled. Preferably the graft is placed in another location than the previous one. Treatment of the infected graft is associated with hospitalization and thus high care cost 36, 56 . Typical therapeutic models for graft infection treatment mentioned above have obvious disadvantages. The main disadvantage is that no alternative localization exists for the placement of the graft. This is the situation when attempts for angioaccess have been repetitively performed on the opposite upper extremity and all have failed, or the central venous system is obturated. Other materials were used as a substitution for autologous vessel circulation to solve this problem.
In 2000 Matsura et al. 91 published a prospective study outcome. The authors used a cryopreserved femoral vein instead of prosthesis in the infected field, or when all others modalities for angioaccess were attrited. The relative resistance to infection of this material was confirmed. The material was used in the field of infection in 38 patients. In 20 patients, infected ePTFE prosthesis was replaced by the cryopreserved vein in one session. No new infection nor any other complication such as bleeding or pseudoaneurysm of the cryopreserved graft appeared. One year primary cumulative function was 49% and secondary patency was 75%. In comparision with a group of 68 patients with implanted ePTFE proshesis, the patency of the graft was similar and the resistance to infection was higher in the group with the cryopreserved graft 91 . In 20 patients at high risk for infection Bolton et al. 92 used the cryopreserved femoral vein. The localization of the vein was the thigh, the upper extremity and the chest. They failed to confirm the positive results of Matsura et al. 91 There was sepsis in 15% of patients in their group, local infection in 40% and 6 patients experienced massive hemorrhage from infection. Bolton et al. 92 consider the risk of infection in the cryopreserved vein high, especially when placed in the subcutis of the thigh. They believe that replacement of the infected ePTFE graft by the cryopreserved vein is indicated only if there is no other option available.
In another study published in 2002 further experiences with cryopreserved femoral vein or great saphenous vein harvested from the regularly examined organ transplant donors were discussed. The vein was used in 38 patients and the one year cumulative function was 68%. In this group of patients, no infection of the cryopreserved vein was seen, the aneurysmatic dilatation of the vein was found twice. The clinical signs of allograft rejection did not occur 93 . The potential of cryopreserved vein grafts were also evaluated in 2004 and 2005 by Madden et al. 94, 95 . In their first work they compared the outcomes of ePTFE grafts and cryopreserved veins in infectionfree field. The graft patency was similar, cryopreserved veins were more resistant to infection but tended more to pseudoaneurysm creation. The study followed up with emphasis on stenotic and thrombotic complications since the authors expected the cryopreserved grafts to be more resistant in this respect than ePTFE grafts. The study was interrupted in 2003 when FDA (Food and Drug Administration) imposed security restrictions on tissue processing to the producer. The study showed similar outcomes in terms of stenotic and thrombotic complications in both groups but no infectious complications.
Since cryopreserved veins are more expensive they were not recommended for usage, irrespective of the FDA restriction.
Considering the expense of ePTFE grafts, formaldehyde-fixed arterial allografts began to be used 96 . Femoral arteries were harvested from cadaver organ transplant donors. Graft patency was comparable to other materials, the incidence of infectious complications was low -one patient out of 43, in a total of 68 grafts.
Data shown suggest that ePTFE prosthesis remains the only material for use. The cryopreserved graft appeared to be acceptable for complicated angioaccess in hemodialysed patients with infection complications. It is not clear from current literature findings if cryopreserved veins were further developed or utilized after the FDA restriction. Clinical importance of the cryopreserved veins is related only to single-centre experience. Infectious complications of arteriovenous ePTFE grafts for hemodialysis
CONCLUSION
The arteriovenous graft infection has a significant impact on the morbidity and mortality in hemodialysed patients. A complex approach is required, including prevention, diagnosis and therapy. All measures to decrease the incidence of infection are beneficial and lower the costs of angioaccess care. Observations made during the last thirty years have brought nothing substantially new. The ePTFE prosthesis remains the most appropriate substitute. Prior to implantation, it is necessary to suppress all source of infection. Prosthesis implantation requires compliance with sterile safeguards. Diagnosis of infection is usually established according to clinical findings. The specification in accordance with PET CT examination seems to be a perspective. The principal of therapy remains unchanged. The surgical procedure is fundamental. Type of surgical procedure depends on experience. Apparently it is safer to remove all the infected prosthesis and provide access to dialysis using a central venous catheter. Functionality and length of use of prosthesis can also influence decisions. Prostheses that are repeatedly examined for stenotic and thrombotic complications with suspicion of infection should be removed. Simultaneous antibiotic therapy should correspondent to the results of the susceptibility tests.
